<DOC>
	<DOCNO>NCT01460368</DOCNO>
	<brief_summary>Part A : The purpose Part A study look electrocardiogram ( ECG ) effect due blood sugar change meal compare LY2409021 also give meal . Part B : The purpose Part B evaluate effect LY2409021 , give dose level much high would normally give , electrical activity heart measure ECG relation placebo moxifloxacin .</brief_summary>
	<brief_title>A Study Effects LY2409021 Electrical Impulses Heart</brief_title>
	<detailed_description>This 2 part study . Part A single-dose study compare effect meal glucose , insulin QT healthy participant without LY2409021 . Part B study randomize , 3-period , crossover design , participant investigator blind placebo LY2409021 , assess electrophysiological effect single supratherapeutic dose LY2409021 compare positive control ( moxifloxacin ) placebo .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>overtly healthy male female , determine medical history physical examination female participant : woman childbearing potential due surgical sterilization ( hysterectomy alone least 6 week postsurgical bilateral oophorectomy without hysterectomy tubal ligation ) confirm medical history , menopause Women intact uterus deem postmenopausal â‰¥45 year old , take hormone oral contraceptive within last year , cessation menses least 1 year , 6 12 month amenorrhea folliclestimulating hormone level consistent postmenopausal state body mass index ( BMI ) 18.5 32 kg/m^2 , inclusive , screen fast blood glucose 54 110 mg/dL ( 3.0 6.1 mmol/L ) clinically normal screen ECG measurable QT interval judge central reader , allow accurate measurement QT interval clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator venous access sufficient allow blood sample reliable willing make available duration study willing follow study procedure normal blood pressure pulse rate ( supine ) screening , minor deviation judge acceptable investigator give write informed consent approve Lilly ethical review board ( ERB ) govern site serum magnesium potassium equal low limit normal currently enrol complete discontinue within last 30 day ( screen ) clinical trial involve investigational product ; concurrently enrol type medical research judge scientifically medically compatible study know allergy LY2409021 , related compound component formulation , moxifloxacin person previously receive investigational product study , complete withdrawn study study investigate LY2409021 personal family history long QT syndrome family history sudden unexplained death cardiac death family member 60 year age personal history unexplained syncope within last year history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data regularly use know drug abuse and/or show positive finding urinary drug screen show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody show evidence hepatitis C and/or positive hepatitis C antibody show evidence hepatitis B and/or positive hepatitis B surface antigen woman positive pregnancy test woman lactate intend use overthecounter ( include mineral supplement herbal medicine ) prescription medication within 7 day prior dose donate blood 500 mL within last month average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) , unwilling comply alcohol restriction study ( , refrain alcohol consumption 24 hour prior dose completion treatment period consume 2 unit alcohol per day treatment period participant smoke 10 cigarette per day and/or unable abide study restriction smoking/tobacco use ( , refrain smoke approximately 2 hour prior ECG timepoint total approximately 12 hour participant unable abide study restriction caffeine/xanthine use ( , refrain consume caffeine/xanthine contain drink food ( coffee , tea , cola , chocolate ) day ECGs perform , maintain consistent consumption habit day study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>